salsalate (salflex) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.   NCATS

Chemistry

  • SMILES: OC(=O)C1=CC=CC=C1OC(=O)C2=CC=CC=C2O
  • InChIKey: WVYADZUPLLSGPU-UHFFFAOYSA-N
  • Mol. Mass: 258.2262
  • ALogP: 2.31
  • ChEMBL Molecule:
    salsalate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.5000 - $0.5722
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-carboxyphenyl salicylate | acetylated salicylate | arcylate | argesic | disalcid | disalicylic acid | disalicylsaeure | mono-gesic | o-salicylcylsalicylsaeure | o-salicylsalicylic acid | salflex | salicylic acid bimolecular ester | salicylic acid salicylate | salicyloxysalicylic acid | salicyloylsalicylic acid | salicyl salicylate | salicylsalicylic acid | saloxium | salsalate | salsalato | salsalatum | salsitab | sasapyrin | sasapyrine | sasapyrinum | upsher-smith brand of salicylsalicylic acid

Organizations (35)

Research & Development (35)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (36)

Approved Indications (2)


 

Arthritis, Rheumatoid

Osteoarthritis

Experimental Indications - Clinical Trial Phases 1-4 (35)


 

Alzheimer Disease (Phase 1)

Anemia (Phase 2)

Atherosclerosis (Phase 2/Phase 3)

Bone Marrow Cells (Phase 2)

Cardiovascular Diseases (Phase 2/Phase 3)

Coronary Artery Disease (Phase 2/Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 2/Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Neuropathies (Early Phase 1)

Endometriosis (Early Phase 1)

Endothelial Cells (Phase 2)

Healthy Volunteers (Phase 1)

Heart Failure, Diastolic (Phase 2)

HIV (Phase 2)

Hyperglycemia (Phase 1)

Inflammation (Phase 2/Phase 3)

Insulin Resistance (Phase 2/Phase 3)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 4)

Obesity (Phase 2)

Osteoarthritis (Phase 4)

Overweight (Phase 2/Phase 3)

Peripheral Nervous System Diseases (Phase 2/Phase 3)

Polycystic Ovary Syndrome (Phase 2)

Postoperative Complications (Phase 1)

Prediabetic State (Phase 2)

Pre-Eclampsia (Early Phase 1)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Supranuclear Palsy, Progressive (Phase 1)

Vascular Stiffness (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial Organizations: 35

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue